Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays

Journal of Clinical Microbiology

Volumn 43, Issue 8, 2005, Pages 3963-3970

  Huang, Diana D ^a   Bremer, James W ^a   Brambilla, Donald J ^b   Palumbo, Paul E ^c  

^a RUSH MEDICAL COLLEGE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; ASSAY; CASE REPORT; CODON; COMPUTER PROGRAM; DRUG RESISTANCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODEL; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

ANTI-HIV AGENTS; CODON; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; MUTATION; SEQUENCE ANALYSIS, DNA; TEMPLATES, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 23744498798     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.8.3963-3970.2005     Document Type: Article

References (9)

1. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
2. Erali, M., S. Page, L. G. Reimer, and D. R. Hillyard. 2001. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J. Clin. Microbiol. 39:2157-2165.
3. Hanna, G. J., and R. T. D'Aquila. 2001. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin. Infect. Dis. 32:774-782.
4. Hirsch, M. S., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, R. T. D'Aquila, L. M. Demeter, S. M. Hammer, V. A. Johnson, C. Loveday, J. W. Mellors, D. M. Jacobsen, and D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37:113-128.
5. Hollinger, F. B., J. W. Bremer, L. E. Myers, J. W. Gold, L. McQuay, and The NIH/NIAID/DAIDS/ACTG Virology Laboratories. 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J. Clin. Microbiol. 30:1787-1794.
6. Huang, D. D., S. H. Eshleman, D. J. Brambilla, P. E. Palumbo, and J. W. Bremen 2003. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J. Clin. Microbiol. 41:3265-3272.
7. Perkin-Elmer Corporation. 1995. Comparative PCR sequencing: a guide to sequencing-based mutation detection. Applied Biosystems Division, Perkin-Elmer Corporation, Foster City, CA.
8. Sayer, D. C., S. Land, L. Gizzarelli, M. French, G. Hales, S. Emery, F. T. Christiansen, and E. M. Dax. 2003. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J. Clin. Microbiol. 41:227-236.
9. Shafer, R. W., K. Hertogs, A. R. Zolopa, A. Warford, S. Bloor, B. J. Betts, T. C. Merigan, R. Harrigan, and B. A. Larder. 2001. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J. Clin. Microbiol. 39:1522-1529.